AIRLINK 72.18 Increased By ▲ 0.49 (0.68%)
BOP 4.93 Decreased By ▼ -0.07 (-1.4%)
CNERGY 4.35 Decreased By ▼ -0.04 (-0.91%)
DFML 28.49 Decreased By ▼ -0.06 (-0.21%)
DGKC 81.30 Decreased By ▼ -1.10 (-1.33%)
FCCL 21.50 Decreased By ▼ -0.45 (-2.05%)
FFBL 33.05 Decreased By ▼ -1.10 (-3.22%)
FFL 9.86 Decreased By ▼ -0.22 (-2.18%)
GGL 10.48 Increased By ▲ 0.36 (3.56%)
HBL 114.00 Increased By ▲ 1.00 (0.88%)
HUBC 140.00 Decreased By ▼ -0.50 (-0.36%)
HUMNL 9.03 Increased By ▲ 1.00 (12.45%)
KEL 4.73 Increased By ▲ 0.35 (7.99%)
KOSM 4.38 Decreased By ▼ -0.12 (-2.67%)
MLCF 37.65 Decreased By ▼ -0.36 (-0.95%)
OGDC 133.70 Decreased By ▼ -0.99 (-0.74%)
PAEL 25.60 Decreased By ▼ -1.02 (-3.83%)
PIAA 23.98 Decreased By ▼ -1.42 (-5.59%)
PIBTL 6.48 Decreased By ▼ -0.07 (-1.07%)
PPL 122.62 Increased By ▲ 0.67 (0.55%)
PRL 27.07 Decreased By ▼ -0.66 (-2.38%)
PTC 13.60 Decreased By ▼ -0.20 (-1.45%)
SEARL 56.62 Increased By ▲ 1.73 (3.15%)
SNGP 69.24 Decreased By ▼ -0.46 (-0.66%)
SSGC 10.34 Decreased By ▼ -0.06 (-0.58%)
TELE 8.45 Decreased By ▼ -0.05 (-0.59%)
TPLP 11.28 Increased By ▲ 0.33 (3.01%)
TRG 61.21 Increased By ▲ 0.31 (0.51%)
UNITY 25.33 Increased By ▲ 0.11 (0.44%)
WTL 1.50 Increased By ▲ 0.22 (17.19%)
BR100 7,630 Decreased By -8.3 (-0.11%)
BR30 24,990 Increased By 18.4 (0.07%)
KSE100 72,602 Decreased By -159.4 (-0.22%)
KSE30 23,539 Decreased By -86.6 (-0.37%)

Chinese firm gets approval to begin human testing for potential coronavirus vaccine

  • Vaccine is co-developed by Anhui Zhifei Longcom Biopharmaceutical and the Institute of Microbiology of the Chinese Academy of Sciences.
Published June 23, 2020
People wear face masks as they arrive at Beijing Capital International Airport in Beijing, January 25, 2020.  REUTERS/Thomas Peter
People wear face masks as they arrive at Beijing Capital International Airport in Beijing, January 25, 2020. REUTERS/Thomas Peter

China has approved a coronavirus vaccine candidate developed by Chongqing Zhifei Biological Products' unit to begin human testing, the company said in a filing on Tuesday.

The potential vaccine, co-developed by Anhui Zhifei Longcom Biopharmaceutical and the Institute of Microbiology of the Chinese Academy of Sciences, has received a certificate from the National Medical Products Administration to launch clinical trials.

Chinese researchers and companies are testing six experimental shots in humans, and more than a dozen vaccines are in different stages of clinical trials globally against the virus that has killed over 470,000 people.

However, none of the them have passed large-scale, late-stage phase 3 clinical trials, a necessary step before entering the consumer market.

Comments

Comments are closed.